In the ESR1-MUT situation, AI is ineffective since ESR1-MUT does not require estrogen, and tamoxifen and fulvestrant bind less strongly to ESR1-MUT. PI3Ki and mTORC1i theoretically remain effective, although the crosstalk between ESR1-MUT and PI3K/mTORC1 signaling is not known. Table 2 Novel SERM, SERCA, and SERD drugs targeting ER Full size table In summary, ESR1-MUT does not appear to be a main mechanism of resistance to tamoxifen, and the SERM lasofoxifene, SERM/SERD bazedoxifene, and SERCA H3B-6545 are all options in-development for endocrine-resistant and ESR1-MUT MBC. ESR1 mutations and selective estrogen receptor degraders Despite relative resistance of ESR1-MUT to fulvestrant in pharmacokinetic studies in the laboratory, clinical studies show conflicting results regarding ESR1-MUT and response to fulvestrant. Similar results were obtained in the SoFEA and EFECT trials, which were discussed above regarding effects of ESR1-MUT in the AI arms [42 ]. Although ESR1-MUT predicted poor PFS and OS on exemestane, ESR1-MUT benefitted from fulvestrant, such that ESR1-MUT and ESR1-WT on fulvestrant had similar outcomes. In theory, ESR1-MUT would not confer resistance to CDK4/6i, as ER is upstream of Cyclin D-CDK4/6 inactivation of RB and derepression of E2F activity [59 ]. Consistent with this, in preclinical work, endocrine-resistant and ESR1-MUT breast cancer cells retain palbociclib sensitivity, and PDX models with ESR1-MUT also remain sensitive to palbociclib and abemaciclib.

Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Google Scholar Steele, C., Cowsert, L. M. & Shillitoe, E. J. Effects of human papillomavirus type 18-specific antisense oligonucleotides on the transformed phenotype of human carcinoma cell lines. Article PubMed PubMed Central CAS Google Scholar Yoshida, M., Seiki, M., Yamaguchi, K. & Takatsuki, K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Article CAS PubMed Google Scholar Oh, S. T., Kyo, S. & Laimins, L. A. Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites.

A review published in The American Journal of Clinical Oncology casts doubt on the accuracy of studies that conclude radiation from medical imaging causes cancer. The review argues that studies that claim that there is “no safe dose” of ionising radiation have ignored the plethora of studies which take the opposite point of view. It points out that campaigns to reduce the use of medical imaging studies based on perceived risk:benefit ratio assumptions remain erroneous if the linear no-threshold hypothesis of radiation carcinogenesis is also wrong. The publication argues that while radiation is known to cause cancer at high doses and high-dose rates, no data has ever shown that low doses cause cancer.

54 , 55 Assessment of the mutational status of KRAS , NRAS , and BRAF may be done using real time-polymerase chain reaction or next-generation sequencing on DNA extracted either from the primary tumor or from a metastatic site.56 Recent studies also support the use of liquid biopsy-based approaches for detecting the presence of circulating tumor DNA in the plasma of patients with mCRC.57 Relatively good concordance in the detection of RAS and BRAF mutations in tumor tissues compared with plasma has been reported. 66 Of note, these RTK gene rearrangements are more frequent in patients with right-sided primary CRC, RAS/BRAF WT tumors, and MSI-H tumors. Frequency is higher in localized CRC compared with mCRC: approximately 20% in stage II tumors, 12% in stage III tumors, and 5% in stage IV tumors. CMS4 tumors are more often diagnosed in advanced-disease stage with poorer relapse-free survival and OS. Recently, a translational study that included more than 1700 primary tumor samples from patients treated on the PETACC-8 adjuvant trial, reported that, in 55% of tumor samples, ≥2 CMS groups could be identified.

Data points are cell-based data, bar represents the mean S.D. n = 32 cells aggregated from 3 independent immunostainings. 7c. Left panel shows a normal anaphase cell; right panel shows a cell with a lagging centromere-positive chromosome. F , Quantitation of micronuclei-positive cells in MDA-MB-436 cells transduced with an either empty virus or B6L-expressing virus following addition of AS1. C , Analysis of cell viability by CellTiter GLo of the indicated DLD1 cell lines following celastrol or TD-52 treatments at the indicated concentrations.

A study conducted by researchers from the University of Michigan has identified DNA methylation markers associated with breast cancer (BC) mortality and progression that are specific to tumor subtype and menopausal status. The researchers analyzed data from the Cancer Genome Atlas participants using the Illumina Infinium HumanMethylation450 BeadChip array and identified eight CpG probes associated with survival outcomes. Of these, six presented lower risks of all-cause mortality or BC progression with higher DNAm. The detected site-specific probes were validated with consistent directions and magnitudes of effects on prognosis across two independent datasets. The researchers believe their findings could improve prognosis prediction for BC patients, thus contributing to tailored therapeutic regimens. Future studies with larger independent datasets are required for replication and functional implications of detected DNAm.

Even though Adjuvant Endocrine Therapy had significantly increased overall survival in the long-run, some studies have reported suboptimal treatment adherence rates, varying from 40-95.7%. One possible cause for this great variability on AET adherence is the patients' expenses on treatment. The questionnaire applied in this study included objective questions that aimed to understand the systemic endocrine therapy adherence among Breast Cancer patients. A linear regression model was built using the MG test as dependent variable, and how the patients obtained the drugs as independent variable, controlled by other sociodemographic and clinical covariates. Patients obtained the drugs mainly via Health Insurance, followed by the SUS and private health expenses.

The use of relative survival (RS) estimates is widespread in cancer registries due to their independence from cause of death information. A study conducted by the Cancer Registry of Norway analyzed 5-year cause-specific survival (CSS) estimates and 5-year RS estimates for various cancer sites, categorized by age and time since diagnosis. The study found that RS estimates provide reliable results for most cancer sites, with only small discrepancies observed between RS and CSS estimates. Possible explanations for these discrepancies include comorbidities and advances in cancer treatments. The study concludes that RS estimates are a valuable tool for comparing cancer survival rates across different populations and treatment settings.

Researchers have assessed the utility of a panel of four circulating protein biomarkers (4MP) integrated with a risk model based on patient characteristics, to identify individuals at high risk of lethal lung cancer. Data from a 4MP protein panel previously assayed in pre-diagnostic sera from 552 lung cancer cases and 2,193 non-cases were used in the study. A logistic regression model that combined the 4MP with the PLCOm2012 risk model showed strong performance as a risk prediction tool for lung cancer death. Among cases only, at the 1.0%/6-year risk threshold the cumulative incidence of lung cancer death was statistically significantly higher in ‘test positive’ cases compared to ‘test negative’ cases. The adjusted sub distributional hazard ratio for ‘test positive’ cases was 1.67 and the adjusted lung-cancer death-specific hazard ratio for ‘test positive’ cases was 2.02. The results suggest that the blood-based biomarker panel in combination with PLCOm2012 identifies individuals at high risk of a fatal form of lung cancer.

The text lists six research articles from various medical journals. The topics range from malformations of the female reproductive system to the need for common nomenclature in radiotherapy. The articles were published between 1990 and 2006. While the text does not offer a conclusion or overarching theme, the articles showcase the diversity of medical research and the various fields within the healthcare industry. The articles may be of interest to medical professionals or individuals with an academic interest in healthcare.